1. Home
  2. ACAD vs AVAL Comparison

ACAD vs AVAL Comparison

Compare ACAD & AVAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$17.18

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Logo Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

AVAL

Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

N/A

Current Price

$3.46

Market Cap

5.1B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ACAD
AVAL
Founded
1993
1994
Country
United States
Colombia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.1B
IPO Year
2000
2011

Fundamental Metrics

Financial Performance
Metric
ACAD
AVAL
Price
$17.18
$3.46
Analyst Decision
Buy
Hold
Analyst Count
20
3
Target Price
★ $30.21
$5.07
AVG Volume (30 Days)
★ 2.4M
227.5K
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
★ 4.25%
EPS Growth
★ 69.12
N/A
EPS
★ 0.51
N/A
Revenue
★ $726,437,000.00
N/A
Revenue This Year
$19.55
$9.63
Revenue Next Year
$13.34
$11.85
P/E Ratio
$34.47
★ $12.86
Revenue Growth
★ 40.45
N/A
52 Week Low
$15.86
$3.35
52 Week High
$30.96
$6.20

Technical Indicators

Market Signals
Indicator
ACAD
AVAL
Relative Strength Index (RSI) 34.82 21.96
Support Level $15.86 $3.35
Resistance Level $22.71 $4.57
Average True Range (ATR) 1.20 0.22
MACD -0.11 -0.07
Stochastic Oscillator 18.38 4.27

Price Performance

Historical Comparison
ACAD
AVAL

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About AVAL Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

Grupo Aval Acciones y Valores SA is a Colombian financial services company. Its segments include: Banking Services segment comprises Banking Services, fund management and trust businesses, storage companies and entities that manage low-value payment systems. Merchant Banking segment comprises Financial Sector (trust and brokerage), Gas and Energy Sector (includes natural gas and energy transportation and distribution businesses), Infrastructure Sector (includes road infrastructure projects, construction services, and operation and maintenance), Hotel Sector (includes hospitality services), Agribusiness Sector (includes palm oil, rubber and rice businesses). Pension and Severance Fund Management segment comprise administrator of pension and severance funds; and Holding segment.

Share on Social Networks: